Neuraptive Therapeutics Announces FDA has Granted Fast Track Designation to NTX-001 Clinical Development Program for Treatment of Patients with Peripheral Nerve Injuries

PHILADELPHIA--(BUSINESS WIRE)--May 14, 2020 -- Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for treatment of peripheral nerve injuries (PNI), today...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials